In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Clinical research worldwide is rapidly transforming through new digital strategies—especially in the field of rare diseases. Recent months …
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
Advanced manufacturing technologies are transforming biopharma production lines, driving efficiency, quality, and scalability to meet growing global demand.
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
A new multinational clinical trial marks a significant step in developing transformative gene therapies for rare inherited disorders.
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Already a subscriber? Log in